This cross-journal Virtual Special Issue is centered around the covalent modulation of targets. Submit your manuscript by March 31, 2024.
Covalent therapies have demonstrated success in the clinic (see, esomeprazole (Nexium; AstraZeneca), clopidogrel (Plavix; Sanofi-Aventis/Bristol-Myers Squibb), ibrutinib (Imbruvica; AbbVie/Janssen) and Nirmatrelvir (Paxlovid; Pfizer)) but, despite this, there has been a reluctance to explore this mode of action broadly in target centric drug discovery programs. However, covalent medicines have seen a surge of interest in the past few years with new biotech companies, and selinexor (XPOVIO; Karyopharm Therapeutics) entering the clinic for modulation of a non-kinase target, a nuclear export protein. With this shifting focus in the community, we are using this Virtual Special Issue to capture the advances that are being made in the field.
We are launching this joint Virtual Special Issue with Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, and ACS Chemical Biology entitled "Exploring Covalent Modulators in Drug Discovery and Chemical Biology," which is being spearheaded by Lori Ferrins (Northeastern University) and Ashley Adams (Exscientia). For more information on this Virtual Special Issue, read our joint Editorial.
Organizing Editors
Lori Ferrins, Topic Editor, Journal of Medicinal Chemistry
Northeastern University, United States
Ashley Adams, Topic Editor, ACS Medicinal Chemistry Letters
Exscientia, United States
Submission Instructions
To submit for this special issue:
- Log in to the ACS Paragon Plus submission site and choose Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, or ACS Chemical Biology.
- Select your manuscript type, and, under "Special Issue Selection," choose "Exploring Covalent Modulators in Drug Discovery and Chemical Biology."
Please see Author Guidelines for Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, or ACS Chemical Biology for more information on submission requirements. The Journal of Medicinal Chemistry will publish Perspectives, Articles, and Drug Annotations that highlight the discovery and development of covalent modulators across all disease areas. ACS Medicinal Chemistry Letters welcomes Letters, Notes, Technical Notes, Microperspectives, and Viewpoints that showcase either the drug discovery process or the development of transformative technologies to pursue this modality. ACS Chemical Biology invites the submission of Letters, Articles, Reviews, and Perspectives that embrace the interface between chemistry and biology as it relates to covalent modulators of activity. Manuscripts will still show structure−activity and structure-property relationship studies using state-of-the-art medicinal chemistry and bioassay technologies, and those that detail the combination of carefully tuned reactivity with specific complementarity to the target are strongly encouraged.
The deadline for submissions is March 31, 2024.
Stay Connected with These Journals
